Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?
Michael BaboudjianMathieu RoumiguiéAlexandre PeltierMarco OderdaEric BarretGaëlle FromontCharles DarianeGaelle FiardAnne-Laure CharvetBastien Gondran-TellierCamille Durand-LabruniePierre Vincent CampelloThierry RoumeguèreRomain DiamandPietro DianaAlae TouzaniJean-Baptiste BeauvalLaurent DanielMorgan RouprêtAlain RuffionGuillaume Ploussardnull nullPublished in: World journal of urology (2022)
In this European study, we showed that there is still a risk of underestimating GGG1 disease at biopsy despite the routine use of image-guided biopsies. Future studies are warranted to improve the detection of aggressive disease in GGG1-labeled patients by incorporating the latest tools such as genomic testing or radiomics.
Keyphrases
- prostate cancer
- end stage renal disease
- ultrasound guided
- chronic kidney disease
- ejection fraction
- newly diagnosed
- deep learning
- squamous cell carcinoma
- radical prostatectomy
- stem cells
- magnetic resonance
- machine learning
- prognostic factors
- clinical practice
- mesenchymal stem cells
- contrast enhanced
- patient reported outcomes
- lymph node metastasis
- genome wide